

Alvaro N A Monteiro

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6438350/alvaro-n-a-monteiro-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

170
papers

7,854
citations

47
h-index

84
g-index

225
ext. papers

9,167
ext. citations

7.6
avg, IF

5.35
L-index

#	Paper	IF	Citations
170	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
169	Evidence for a transcriptional activation function of BRCA1 C-terminal region. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 13595-9	11.5	391
168	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. <i>American Journal of Human Genetics</i> , 2007 , 81, 873-83	11	360
167	Principles for the post-GWAS functional characterization of cancer risk loci. <i>Nature Genetics</i> , 2011 , 43, 513-8	36.3	326
166	BRCA1 regulates p53-dependent gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 2302-6	11.5	317
165	Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. <i>American Journal of Human Genetics</i> , 2004 , 75, 535-44	11	312
164	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 362-70, 370e1-2	36.3	267
163	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. <i>Human Mutation</i> , 2012 , 33, 2-7	4.7	211
162	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
161	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015 , 47, 164-71	36.3	177
160	A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). <i>Human Mutation</i> , 2012 , 33, 8-21	4.7	143
159	BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. <i>Annals of Oncology</i> , 2015 , 26, 2057-65	10.3	124
158	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013 , 4, 1628	17.4	124
157	Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. <i>Human Molecular Genetics</i> , 2001 , 10, 353-60	5.6	123
156	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811	5.8	121
155	Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. <i>Cancer Research</i> , 2010 , 70, 4880-90	10.1	113
154	A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. <i>Nature Communications</i> , 2016 , 7, 11743	17.4	113

153	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. <i>Cancer Discovery</i> , 2013 , 3, 399-405	24.4	106
152	Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. <i>Human Molecular Genetics</i> , 2015 , 24, 5356-66	5.6	104
151	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	24.4	104
150	p53 acetylation is crucial for its transcription-independent proapoptotic functions. <i>Journal of Biological Chemistry</i> , 2009 , 284, 11171-83	5.4	99
149	Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. <i>Cancer Research</i> , 2007 , 67, 1494-501	10.1	98
148	A guide for functional analysis of BRCA1 variants of uncertain significance. <i>Human Mutation</i> , 2012 , 33, 1526-37	4.7	94
147	Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. <i>Cancer Research</i> , 2004 , 64, 3790-7	10.1	92
146	A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. <i>Oncotarget</i> , 2015 , 6, 34745-57	3.3	92
145	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013 , 4, 1627	17.4	85
144	Assessment of functional effects of unclassified genetic variants. <i>Human Mutation</i> , 2008 , 29, 1314-26	4.7	85
143	Cancer variation associated with the position of the mutation in the BRCA2 gene. <i>Familial Cancer</i> , 2004 , 3, 1-10	3	77
142	Functional assays for analysis of variants of uncertain significance in BRCA2. <i>Human Mutation</i> , 2014 , 35, 151-64	4.7	75
141	BRCA1: exploring the links to transcription. <i>Trends in Biochemical Sciences</i> , 2000 , 25, 469-74	10.3	75
140	Charting the landscape of tandem BRCT domain-mediated protein interactions. <i>Science Signaling</i> , 2012 , 5, rs6	8.8	74
139	Classification of BRCA1 missense variants of unknown clinical significance. <i>Journal of Medical Genetics</i> , 2005 , 42, 138-46	5.8	73
138	LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. <i>Cancer Research</i> , 2011 , 71, 3896-903	10.1	70
137	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	65
136	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016 , 7, 11375	17.4	64

135	A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. <i>Cancer</i> , 2015 , 121, 4173-80	6.4	64
134	Phosphatases in the cellular response to DNA damage. <i>Cell Communication and Signaling</i> , 2010 , 8, 27	7.5	62
133	Establishment of a continuous cell line from fibrotic schistosomal granulomas in mice livers. <i>In Vitro Cellular and Developmental Biology - Plant</i> , 1985 , 21, 382-90	2.3	61
132	Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 349-53	4.4	59
131	Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. <i>Cell Chemical Biology</i> , 2016 , 23, 1490-1503	8.2	58
130	Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. <i>Npj Genomic Medicine</i> , 2016 , 1,	6.2	55
129	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
128	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019 , 40, 1557-1578	4.7	52
127	BRCA1: the enigma of tissue-specific tumor development. <i>Trends in Genetics</i> , 2003 , 19, 312-5	8.5	50
126	Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 2789-2799	10.1	49
125	The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 441-53	4.4	49
124	Functional impact of missense variants in BRCA1 predicted by supervised learning. <i>PLoS Computational Biology</i> , 2007 , 3, e26	5	47
123	The Role of PALB2 in the DNA Damage Response and Cancer Predisposition. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	45
122	Functional assays for BRCA1 and BRCA2. <i>International Journal of Biochemistry and Cell Biology</i> , 2007 , 39, 298-310	5.6	44
121	A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1078-88	4	42
120	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015 , 6, 8234	17.4	40
119	Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. <i>American Journal of Human Genetics</i> , 2018 , 102, 233-248	11	38
118	Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity. <i>ACS Chemical Biology</i> , 2017 , 12, 1883-1892	4.9	36

117	Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. <i>Genetics in Medicine</i> , 2019 , 21, 71-80	8.1	36
116	Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. <i>European Journal of Human Genetics</i> , 2008 , 16, 820-32	5.3	36
115	Breast cancer susceptibility and the DNA damage response. <i>Cancer Control</i> , 2005 , 12, 127-36	2.2	36
114	Circadian pathway genes in relation to glioma risk and outcome. <i>Cancer Causes and Control</i> , 2014 , 25, 25-32	2.8	35
113	Differences in BRCA counseling and testing practices based on ordering provider type. <i>Genetics in Medicine</i> , 2015 , 17, 51-7	8.1	34
112	Identification of Filamin A as a BRCA1-interacting protein required for efficient DNA repair. <i>Cell Cycle</i> , 2010 , 9, 1421-33	4.7	34
111	A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants. <i>Nature Genetics</i> , 2019 , 51, 815-823	36.3	33
110	BRCT domains: A little more than kin, and less than kind. <i>FEBS Letters</i> , 2012 , 586, 2711-6	3.8	33
109	Rare TP53 genetic variant associated with glioma risk and outcome. <i>Journal of Medical Genetics</i> , 2012 , 49, 420-1	5.8	33
108	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015 , 24, 3595-607	5.6	32
107	Common BRCA1 variants and transcriptional activation. <i>American Journal of Human Genetics</i> , 1997 , 61, 761-2	11	32
106	Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009 , 660, 1-11	3.3	31
105	Understanding germ-line mutations in BRCA1. <i>Cancer Biology and Therapy</i> , 2004 , 3, 515-20	4.6	30
104	Clinical testing of and : a worldwide snapshot of technological practices. <i>Npj Genomic Medicine</i> , 2018 , 3, 7	6.2	29
103	Mutational heterogeneity in non-serous ovarian cancers. <i>Scientific Reports</i> , 2017 , 7, 9728	4.9	29
102	BRCA1 Circos: a visualisation resource for functional analysis of missense variants. <i>Journal of Medical Genetics</i> , 2015 , 52, 224-30	5.8	28
101	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 505-517	10.1	28
100	Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. <i>Breast Journal</i> , 2013 , 19, 189-92	1.2	27

99	Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. <i>Clinical Genetics</i> , 2014 , 85, 49-53	4	25
98	An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. <i>Cancer Research</i> , 2019 , 79, 1263-1273	10.1	24
97	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1574-84	4	24
96	Negative regulation of CHK2 activity by protein phosphatase 2A is modulated by DNA damage. <i>Cell Cycle</i> , 2010 , 9, 736-47	4.7	23
95	Specificity in signaling by c-Yes. <i>Frontiers in Bioscience - Landmark</i> , 2003 , 8, s185-205	2.8	23
94	Characterization of LGALS3 (galectin-3) as a player in DNA damage response. <i>Cancer Biology and Therapy</i> , 2014 , 15, 840-50	4.6	22
93	BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines. <i>American Journal of Pathology</i> , 2010 , 176, 1203-14	5.8	22
92	In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. <i>Cancer Investigation</i> , 2010 , 28, 172-80	2.1	22
91	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015 , 2,		22
90	A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor. <i>Nucleic Acids Research</i> , 2019 , 47, 10662-10677	20.1	22
89	Functional analysis of the 11q23.3 glioma susceptibility locus implicates PHLDB1 and DDX6 in glioma susceptibility. <i>Scientific Reports</i> , 2015 , 5, 17367	4.9	21
88	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015 , 36, 1341-53	4.6	20
87	BRCA1 in breast and ovarian cancer predisposition. <i>Cancer Letters</i> , 2005 , 227, 1-7	9.9	20
86	Functional characterization of 84 PALB2 variants of uncertain significance. <i>Genetics in Medicine</i> , 2020 , 22, 622-632	8.1	20
85	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. <i>Journal of Medical Genetics</i> , 2019 , 56, 347-357	5.8	19
84	Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. <i>Journal of Biological Chemistry</i> , 2019 , 294, 5980-5992	5.4	19
83	Lessons from postgenome-wide association studies: functional analysis of cancer predisposition loci. <i>Journal of Internal Medicine</i> , 2013 , 274, 414-24	10.8	19
82	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017 , 116, 524-535	8.7	18

81	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015 , 39, 689-97	2.6	18
80	DNA damage response and repair in perspective: <i>Aedes aegypti</i> , <i>Drosophila melanogaster</i> and <i>Homo sapiens</i> . <i>Parasites and Vectors</i> , 2019 , 12, 533	4	17
79	PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1669-81	6.1	17
78	Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. <i>Journal of Medical Genetics</i> , 2006 , 43, 424-8	5.8	16
77	BRCA1 can stimulate gene transcription by a unique mechanism. <i>EMBO Reports</i> , 2000 , 1, 260-5	6.5	16
76	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015 , 10, e0128106	3.7	15
75	A naturally occurring allele of BRCA1 coding for a temperature-sensitive mutant protein. <i>Cancer Biology and Therapy</i> , 2002 , 1, 497-501	4.6	15
74	Yeast-based assays for detection and characterization of mutations in BRCA1. <i>Breast Disease</i> , 1998 , 10, 61-70	1.6	15
73	Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patients. <i>Molecular Carcinogenesis</i> , 2015 , 54 Suppl 1, E172-84	5	14
72	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. <i>Journal of Medical Genetics</i> , 2020 , 57, 509-518	5.8	14
71	Functional and structural analysis of C-terminal BRCA1 missense variants. <i>PLoS ONE</i> , 2013 , 8, e61302	3.7	14
70	Cancer risk assessment at the atomic level. <i>Cancer Research</i> , 2006 , 66, 1897-9	10.1	14
69	Liver connective tissue cells isolated from human schistosomal fibrosis or alcoholic cirrhosis represent a modified phenotype of smooth muscle cells. <i>Biology of the Cell</i> , 1985 , 53, 231-8	3.5	14
68	Tandem BRCT Domains: DNA's Praetorian Guard. <i>Genes and Cancer</i> , 2010 , 1, 1140-6	2.9	13
67	Ectopic expression of histone H2AX mutants reveals a role for its post-translational modifications. <i>Cancer Biology and Therapy</i> , 2009 , 8, 422-34	4.6	13
66	Brain tumor risk according to germ-line variation in the MLLT10 locus. <i>European Journal of Human Genetics</i> , 2015 , 23, 132-4	5.3	12
65	DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis. <i>Cancer Biology and Therapy</i> , 2017 , 18, 439-449	4.6	12
64	DNA damage response: determining the fate of phosphorylated histone H2AX. <i>Cancer Biology and Therapy</i> , 2006 , 5, 142-4	4.6	12

63	Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance. <i>American Journal of Human Genetics</i> , 2021 , 108, 458-468	11	12
62	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	12
61	Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009 , 9, 543-9	2.2	11
60	Fine tuning chemotherapy to match BRCA1 status. <i>Biochemical Pharmacology</i> , 2010 , 80, 647-53	6	11
59	Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation. <i>Cancer Biology and Therapy</i> , 2002 , 1, 502-8	4.6	11
58	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016 , 7, 72381-72394	3.3	11
57	Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. <i>Cancer Research</i> , 2019 , 79, 467-481	10.1	11
56	CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI. <i>Cell Death Discovery</i> , 2019 , 5, 105	6.9	10
55	Network of Interactions between ZIKA Virus Non-Structural Proteins and Human Host Proteins. <i>Cells</i> , 2020 , 9,	7.9	10
54	Functional annotation signatures of disease susceptibility loci improve SNP association analysis. <i>BMC Genomics</i> , 2014 , 15, 398	4.5	10
53	Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations. <i>Cancer Cell International</i> , 2013 , 13, 70	6.4	10
52	Absence of constitutional H2AX gene mutations in 101 hereditary breast cancer families. <i>Journal of Medical Genetics</i> , 2003 , 40, e51	5.8	10
51	Participation of BRCA1 in the DNA repair response...via transcription. <i>Cancer Biology and Therapy</i> , 2002 , 1, 187-8	4.6	10
50	Germline Missense Variants in : New Trends and Challenges for Clinical Annotation. <i>Cancers</i> , 2019 , 11,	6.6	9
49	Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	9
48	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018 , 13, e0197561	3.7	9
47	Yeast two-hybrid junk sequences contain selected linear motifs. <i>Nucleic Acids Research</i> , 2011 , 39, e128	20.1	9
46	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. <i>Human Molecular Genetics</i> , 2016 , 25, 3600-3612	5.6	9

45	Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1117-1126	4	8
44	Enhancer scanning to locate regulatory regions in genomic loci. <i>Nature Protocols</i> , 2016 , 11, 46-60	18.8	8
43	In vitro formation of fibrous septa by liver connective tissue cells. <i>In Vitro Cellular & Developmental Biology</i> , 1987 , 23, 10-4		8
42	BRCA1 recruitment to damaged DNA sites is dependent on CDK9. <i>Cell Cycle</i> , 2017 , 16, 665-672	4.7	7
41	Long-term culture of cholangiocytes from liver fibro-granulomatous lesions. <i>BMC Gastroenterology</i> , 2006 , 6, 13	3	7
40	TGF beta1 and PDGF AA override collagen type I inhibition of proliferation in human liver connective tissue cells. <i>BMC Gastroenterology</i> , 2004 , 4, 30	3	7
39	A targeted genetic association study of epithelial ovarian cancer susceptibility. <i>Oncotarget</i> , 2016 , 7, 7381-9	3.9	7
38	Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico. <i>Scientific Reports</i> , 2019 , 9, 17769	4.9	7
37	The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews. <i>Genetic Testing and Molecular Biomarkers</i> , 2006 , 10, 200-7		6
36	Functional implications of BRCA1 for early detection, prevention, and treatment of breast cancer. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2006 , 16, 233-52	1.3	6
35	Early transcriptional response of human ovarian and fallopian tube surface epithelial cells to norepinephrine. <i>Scientific Reports</i> , 2018 , 8, 8291	4.9	6
34	A nuclear function for the tumor suppressor BRCA1. <i>Histology and Histopathology</i> , 2000 , 15, 299-307	1.4	6
33	Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 116-125	4	5
32	Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1. <i>PLoS ONE</i> , 2014 , 9, e97766	3.7	5
31	Interaction of human liver connective tissue cells, skin fibroblasts and smooth muscle cells with collagen gels. <i>Hepatology</i> , 1987 , 7, 665-71	11.2	5
30	Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. <i>Genetics in Medicine</i> , 2021 , 23, 306-315	8.1	5
29	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019 , 8, 2503-2513	4.8	4
28	Involvement of the SH3 domain in Ca ²⁺ -mediated regulation of Src family kinases. <i>Biochimie</i> , 2006 , 88, 905-11	4.6	4

27	Genetic testing and clinical management practices for variants in non-BRCA1/2 breast (and/or ovarian) cancer susceptibility genes: An international survey by the Enigma Clinical Working Group.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1539-1539	2.2	4
26	No Evidence for the Pathogenicity of the BRCA2 c.6937 + 594T>G Deep Intronic Variant: A Case-Control Analysis. <i>Genetic Testing and Molecular Biomarkers</i> , 2018 , 22, 85-89	1.6	3
25	Somatic alterations in brain tumors. <i>Oncology Reports</i> , 2008 , 20, 203-10	3.5	3
24	The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. <i>Cell Chemical Biology</i> , 2021 ,	8.2	3
23	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
22	Functional Landscape of Common Variants Associated with Susceptibility to Epithelial Ovarian Cancer. <i>Current Epidemiology Reports</i> , 2020 , 7, 49-57	2.9	2
21	Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect. <i>Human Molecular Genetics</i> , 2016 , 25, 5287-5299	5.6	2
20	The accidental cancer geneticist: hilão de gouvã and hereditary retinoblastoma. <i>Cancer Biology and Therapy</i> , 2007 , 6, 811-3	4.6	2
19	Complement-dependent induction of DNA synthesis and cell proliferation in human liver connective tissue cells in vitro. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1995 , 31, 149-55	2.6	2
18	Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations		2
17	Response. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	2
16	Lessons learned from two decades of BRCA1 and BRCA2 genetic testing: the evolution of data sharing and variant classification. <i>Genetics in Medicine</i> , 2019 , 21, 1476-1480	8.1	2
15	epiTAD: a web application for visualizing chromosome conformation capture data in the context of genetic epidemiology. <i>Bioinformatics</i> , 2019 , 35, 4462-4464	7.2	1
14	What can yeast tell us about breast cancer?. <i>Cell Cycle</i> , 2017 , 16, 157-158	4.7	1
13	Incorporating computational resources in a cancer research program. <i>Human Genetics</i> , 2015 , 134, 467-786.3		1
12	Principles for the post-GWAS functional characterisation of risk loci. <i>Nature Precedings</i> , 2010 ,		1
11	Three-color intranuclear staining for measuring mitosis and apoptosis in cells transfected with a GFP-tagged histone. <i>Biotechnic and Histochemistry</i> , 2010 , 85, 127-131	1.8	1
10	Somatic alterations in brain tumors. <i>Oncology Reports</i> , 2008 ,	3.5	1

9	Correction: functional analysis of BRCA1 M1628V variant. <i>Journal of Medical Genetics</i> , 2007 , 44, e78	5.8	1
8	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
7	Phase II trial of AZD1775 in combination with carboplatin and paclitaxel in stage IV squamous cell lung cancer (sqNSCLC): Preliminary results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20672-e20672	2.2	1
6	PALB2 Variants: Protein Domains and Cancer Susceptibility. <i>Trends in Cancer</i> , 2021 , 7, 188-197	12.5	1
5	Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells. <i>Scientific Reports</i> , 2021 , 11, 14334	4.9	0
4	CHEKING out of mitosis. <i>Cell Cycle</i> , 2012 , 11, 1756	4.7	
3	Acceptability and outcomes of multigene panel testing among young Black breast cancer survivors. <i>Breast Journal</i> , 2020 , 26, 2112-2114	1.2	
2	Functional evidence (II) protein and enzyme function 2021 , 145-168		
1	Scratching Below the Ovarian Cancer GWAS Surface. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1604-1606	4	